ES2107454T3 - Segmentos extracelulares de peptidos de anclaje de la inmunoglobulina ige humana, y anticuerpos especificos para los mismos. - Google Patents

Segmentos extracelulares de peptidos de anclaje de la inmunoglobulina ige humana, y anticuerpos especificos para los mismos.

Info

Publication number
ES2107454T3
ES2107454T3 ES91904413T ES91904413T ES2107454T3 ES 2107454 T3 ES2107454 T3 ES 2107454T3 ES 91904413 T ES91904413 T ES 91904413T ES 91904413 T ES91904413 T ES 91904413T ES 2107454 T3 ES2107454 T3 ES 2107454T3
Authority
ES
Spain
Prior art keywords
ige
membrane
specific antibodies
human ige
extracellular segments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91904413T
Other languages
English (en)
Inventor
Tse Wen Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/468,766 external-priority patent/US5260416A/en
Priority claimed from US07/515,604 external-priority patent/US5274075A/en
Application filed by Tanox Inc filed Critical Tanox Inc
Application granted granted Critical
Publication of ES2107454T3 publication Critical patent/ES2107454T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

SE PRESENTAN EPITOPOS ANTIGENICOS ASOCIADOS CON SEGMENTOS EXTRACELULARES DEL DOMINANTE QUE UNE LAS INMUNOGLUBULINAS A LA MEMBRANA DE LA CELULA B. PARA IGE, LOS EPITOPOS ESTAN PRESENTES SOBRE LAS CELULAS B QUE SOPORTAN IGE PERO NO ESTAN PRESENTES LOS BASOFILOS O LA FORMA SECRETADA, SOLUBLE DE IGE. LOS EPITOPOS PUEDEN USARSE PARA TERAPIA Y DIAGNOSIS. POR EJEMPLO, LOS ANTICUERPOS O INMUNOTOXINAS ESPECIFICAS PARA LOS EPITOPOS ASOCIADOS CON EL DOMINANTE QUE SE UNE AL IGE PUEDEN USARSE PARA DESTRUIR SELECTIVAMENTE O REGULAR LOS LINFOCITOS QUE SOPORTAN IGE, BLOQUEANDO ASI LAS REACCIONES ALERGICAS EN LAS QUE INTERVIENE IGE. SE HAN DESCUBIERTO TRES ISOFORMAS DIFERENTES DEL SEGMENTO TERMINAL C DE LA CADENA EPSILON HUMANA QUE RESULTA DE LAS UNIONES ALTERNATIVAS DEL MRNA EN LA ZONA EXON DE LA MEMBRANA, UNA DE LAS CUALES ES SECRETADA Y NO SE ENCUENTRA UNIDA A LA MEMBRANA.
ES91904413T 1990-01-23 1991-01-23 Segmentos extracelulares de peptidos de anclaje de la inmunoglobulina ige humana, y anticuerpos especificos para los mismos. Expired - Lifetime ES2107454T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/468,766 US5260416A (en) 1987-12-31 1990-01-23 Antigenic epitopes present on membrane-bound but not secreted IgE
US07/515,604 US5274075A (en) 1987-12-31 1990-04-27 Newly identified human epsilon immunoglobulin peptides and related products
US63007790A 1990-12-19 1990-12-19

Publications (1)

Publication Number Publication Date
ES2107454T3 true ES2107454T3 (es) 1997-12-01

Family

ID=27413084

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91904413T Expired - Lifetime ES2107454T3 (es) 1990-01-23 1991-01-23 Segmentos extracelulares de peptidos de anclaje de la inmunoglobulina ige humana, y anticuerpos especificos para los mismos.

Country Status (12)

Country Link
EP (1) EP0512064B1 (es)
JP (1) JP3449712B2 (es)
AT (1) ATE154637T1 (es)
AU (2) AU645783B2 (es)
CA (1) CA2074089C (es)
DE (1) DE69126607T2 (es)
DK (1) DK0512064T3 (es)
ES (1) ES2107454T3 (es)
GR (1) GR3024563T3 (es)
HK (1) HK1002034A1 (es)
SG (1) SG70982A1 (es)
WO (1) WO1991011456A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT673427E (pt) * 1992-07-08 2003-08-29 Unilever Nv Processo para imobilizar enzimas na parede celular de uma celula microbiana atraves da producao de uma proteina de fusao
WO1994020533A1 (en) * 1993-03-11 1994-09-15 Tanox Biosystems, Inc. PEPTIDES REPRESENTING ANTIGENIC EPITOPES OF IgE PRESENT ON B CELL BUT NOT BASOPHIL SURFACE
US5552537A (en) * 1993-03-24 1996-09-03 The Regents Of The University Of California IgE isoforms and methods of use
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
BR9707819A (pt) 1996-03-01 1999-07-27 Novartis Ag Imunogenos peptidicos
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2003096966A2 (en) * 2002-05-21 2003-11-27 Resistentia Pharmaceuticals Ab Chimeric ige polypeptides and host cells
ES2539250T3 (es) 2005-07-25 2015-06-29 Emergent Product Development Seattle, Llc Reducción de células B mediante el uso de moléculas de unión específica a CD37 y de unión específica a CD20
JP5389442B2 (ja) * 2005-09-29 2014-01-15 メディミューン，エルエルシー 膜Ｉｇ特異的抗体を同定する方法および免疫グロブリンを生成する前駆体細胞を標的化するための使用
WO2007131129A2 (en) * 2006-05-03 2007-11-15 Guthrie Foundation For Education & Research Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders
SG172698A1 (en) 2006-06-12 2011-07-28 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
CA2681341A1 (en) 2007-03-22 2008-09-25 Genentech, Inc. Apoptotic anti-ige antibodies
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
PT2401300T (pt) 2009-02-25 2018-04-17 Academia Sinica Anticorpos anti-c[épsilon]mx capazes de se ligar às mige humanas em linfócios b
WO2012138570A2 (en) 2011-04-06 2012-10-11 The Board Of Regents Of The University Of Texas System Modulating bacterial mam polypeptides in pathogenic disease
US9587034B2 (en) 2012-04-20 2017-03-07 Academia Sinica Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains
WO2015013668A1 (en) * 2013-07-26 2015-01-29 Ke Zhang Anti-immunoglobulin e antibodies and methods of use thereof
TWI603979B (zh) * 2013-12-05 2017-11-01 中央研究院 抗人類膜錨定型免疫球蛋白a抗體能夠溶解帶有膜錨定型免疫球蛋白a的b淋巴球與降低免疫球蛋白a 的生產
MY197562A (en) 2015-09-21 2023-06-23 Aptevo Res & Development Llc Cd3 binding polypeptides
JP7286665B2 (ja) 2017-10-31 2023-06-05 ワンネス バイオテック カンパニー リミティド ＩｇＥ介在アレルギー性疾患の治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT89107A (pt) * 1987-11-30 1989-11-30 Idec Pharma Corp Metodo e meios para a seleccao de anticorpos anti-idiotipos e seu uso para o diagnostico, monitorizacao, tratamento e/ou prevencao de doencas cancerosas, da autoimunidade ou infecciosas
EP0407392B2 (en) * 1987-12-31 1998-10-28 Tanox Biosystems, Inc. UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES

Also Published As

Publication number Publication date
CA2074089C (en) 2001-04-10
AU7317991A (en) 1991-08-21
AU645783B2 (en) 1994-01-27
DE69126607T2 (de) 1998-01-15
DE69126607D1 (de) 1997-07-24
JP3449712B2 (ja) 2003-09-22
JPH05504482A (ja) 1993-07-15
EP0512064B1 (en) 1997-06-18
EP0512064A4 (en) 1993-02-17
ATE154637T1 (de) 1997-07-15
AU5214893A (en) 1994-03-03
SG70982A1 (en) 2000-03-21
DK0512064T3 (da) 1997-12-15
WO1991011456A1 (en) 1991-08-08
CA2074089A1 (en) 1991-07-24
GR3024563T3 (en) 1997-12-31
HK1002034A1 (en) 1998-07-24
EP0512064A1 (en) 1992-11-11

Similar Documents

Publication Publication Date Title
ES2107454T3 (es) Segmentos extracelulares de peptidos de anclaje de la inmunoglobulina ige humana, y anticuerpos especificos para los mismos.
ES2142790T3 (es) Epitopos antigenicos presentes sobre iga unida a la membrana pero no secretada.
ATE397457T1 (de) Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen
NO179615C (no) Monoklonale antistoffer eller fragmenter derav som reagerer med kakektin, cellelinjer som produserer dem, prövesett som omfatter dem, samt anvendelse derav in vitro
ES2107518T5 (es) Polimeros estabilizados con heteroatomos en la cadena principal.
TR199901361T2 (xx) S�lfonamid t�revleri, haz�rlanma prosesi ve ila� olarak kullan�mlar�
DK176487D0 (da) Middel til behandling af inflammationer i oejet
DE69738961D1 (de) Screening von verbindungen zu ihrer fähigkeit um die herstellung von beta-amyloid peptiden zu veränderen
DK0633721T3 (da) Rensning af blodplader med 8-metoxypsoralen
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
CY1108320T1 (el) Συνεργια προσδεματος apo-2 και αντισωματος anti-her-2
ATE347585T1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
NO960743L (no) Cellulære preparater, deres fremstilling og terapeutiske anvendelse
ES2150671T3 (es) Compuesto de bencimidazol y su utilizacion como moduladores del complejo de receptores gaba-a.
DE69630955D1 (de) Immortalisierung bzw. desimmortalisierung von zellen
ES2167544T3 (es) Dioxidos de benzotiazina como antagonistas de la endotelina.
GT200300199A (es) Indoles 2,7-sustituidos
DE3854300T2 (de) Lymphocyteninhibierung durch hla-peptide.
ES2103733T3 (es) Procedimiento para combatir el piojo de los peces.
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
ES2193197T3 (es) Craquizacion catalitica com mcm-49.
ATE399176T1 (de) Nonapeptidische ny-eso-1 derivate und deren verwendung
Lappin et al. Effect of histamine on monocyte complement production. II. Modulation of protein secretion, degradation and synthesis.
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
BR0108187A (pt) Moléculas trade e usos relacionados com as mesmas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 512064

Country of ref document: ES